beta-Pinene
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
beta-Pinene is a mono-terpene indicated in combination with other plant-derived compounds for the treatment of bladder, kidney, and urinary stones.
- Generic Name
- beta-Pinene
- DrugBank Accession Number
- DB15574
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 136.238
Monoisotopic: 136.125200515 - Chemical Formula
- C10H16
- Synonyms
- 2(10)-pinene
- nopinene
- pseudopinene
- β-pinene
- External IDs
- FEMA No. 2903
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image URINEX (Enteric-Coated) Soft Gelatin Capsules beta-Pinene (6.2 mg) + Anethole (4 mg) + Borneol (10 mg) + Camphene (15 mg) + Eucalyptol (3 mg) + Fenchone (4 mg) + alpha-Pinene (24.8 mg) Capsule, gelatin coated Oral Pharco Health Sdn. Bhd 2020-09-08 Not applicable Malaysia โรวาคอล beta-Pinene (3.4 mg) + Borneol (5 mg) + Camphene (5 mg) + Eucalyptol (2 mg) + Levomenthol (32 mg) + Menthone (6 mg) + alpha-Pinene (13.6 mg) Capsule บริษัท ดีซีเอช ออริกา (ประเทศไทย) จำกัด 1986-09-25 Not applicable Thailand โรวาทีเน็ก beta-Pinene (6.2 mg) + Anethole (4 mg) + Borneol (10 mg) + Camphene (15 mg) + Eucalyptol (3 mg) + Fenchone (4 mg) + alpha-Pinene (24.8 mg) Capsule บริษัท ดีซีเอช ออริกา (ประเทศไทย) จำกัด 1987-05-22 Not applicable Thailand
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4MS8VHZ1HJ
- CAS number
- 127-91-3
- InChI Key
- WTARULDDTDQWMU-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H16/c1-7-4-5-8-6-9(7)10(8,2)3/h8-9H,1,4-6H2,2-3H3
- IUPAC Name
- 6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptane
- SMILES
- CC1(C)C2CC1C(=C)CC2
References
- General References
- FDA Thailand: Rowatinex (Anethole, Borneol, Camphene, Eucalyptol, Fenchone, Alpha-Pinene, Beta-Pinene) Capsule [Link]
- External Links
- Human Metabolome Database
- HMDB0036560
- KEGG Compound
- C09882
- ChemSpider
- 14198
- 1923811
- ChEBI
- 50025
- ChEMBL
- CHEMBL501351
- Wikipedia
- Beta-Pinene
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, gelatin coated Oral Capsule - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0637 mg/mL ALOGPS logP 3.94 ALOGPS logP 2.86 Chemaxon logS -3.3 ALOGPS Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 43.65 m3·mol-1 Chemaxon Polarizability 17.14 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 129.43732 predictedDeepCCS 1.0 (2019) [M+H]+ 133.21744 predictedDeepCCS 1.0 (2019) [M+Na]+ 142.17662 predictedDeepCCS 1.0 (2019)
Drug created at November 28, 2019 20:25 / Updated at May 14, 2021 01:07